JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Comprehensive analysis of anosmin-1 as a potential biomarker and its correlation with epithelial-mesenchymal transition in advanced gastric cancer

  • 0Department of Pathology, the Affiliated Hospital of Qingdao University, 16 Jiangsu Road, Qingdao, 266000 People's Republic of China.
3 Biotech +

|

June 23, 2025

|

June 23, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Anosmin-1 (ANOS1) is overexpressed in gastric cancer, correlating with poor prognosis and metastasis. Targeting ANOS1 may offer a new therapeutic strategy for gastric cancer patients.

Area Of Science

  • Oncology
  • Molecular Biology
  • Biochemistry

Background

  • Anosmin-1 (ANOS1) is an extracellular matrix (ECM)-related glycoprotein implicated in various tumors.
  • The role of ANOS1 in advanced gastric cancer (GC) and its connection to epithelial-mesenchymal transition (EMT) remain incompletely understood.

Purpose Of The Study

  • To investigate the differential expression, prognostic impact, and potential mechanisms of ANOS1 in advanced gastric cancer.
  • To explore the correlation between ANOS1 expression, tumor invasiveness, EMT, immune infiltration, and drug sensitivity in GC.

Main Methods

  • Analysis of TCGA data for ANOS1 expression and clinical correlation.
  • Immunohistochemistry (IHC) to detect ANOS1 and E-cadherin in GC tissues.
  • Kaplan-Meier survival analysis, Cox regression, and Spearman correlation.
  • Gene Set Enrichment Analysis (GSEA) and assessment of drug sensitivity using the "pRRophetic" R package.

Main Results

  • ANOS1 was significantly overexpressed in advanced GC, associated with poor prognosis, tumor infiltration, lymph node metastasis, advanced TNM stage, and vascular invasion.
  • ANOS1 expression inversely correlated with E-cadherin and positively with EMT-related genes, immune cell infiltration, and immune checkpoints.
  • High ANOS1 expression predicted sensitivity to 5-fluorouracil, dasatinib, and docetaxel.
  • GSEA identified ANOS1 enrichment in ECM receptor interactions, focal adhesion, and TGF-β signaling pathways.

Conclusions

  • ANOS1 overexpression in advanced GC is linked to aggressive tumor behavior and poor survival.
  • ANOS1 may promote GC progression by regulating EMT and influencing the tumor microenvironment.
  • ANOS1 presents potential as a prognostic biomarker and a therapeutic target for gastric cancer.

Keywords: